DK0610345T3 - Kombinerede cellulære og immunosuppressive terapier - Google Patents

Kombinerede cellulære og immunosuppressive terapier

Info

Publication number
DK0610345T3
DK0610345T3 DK92922624T DK92922624T DK0610345T3 DK 0610345 T3 DK0610345 T3 DK 0610345T3 DK 92922624 T DK92922624 T DK 92922624T DK 92922624 T DK92922624 T DK 92922624T DK 0610345 T3 DK0610345 T3 DK 0610345T3
Authority
DK
Denmark
Prior art keywords
cells
foreign
immunosuppressive therapies
combined cellular
reduced
Prior art date
Application number
DK92922624T
Other languages
English (en)
Inventor
A Sherwin Stephen
B Dubridge Robert
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of DK0610345T3 publication Critical patent/DK0610345T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92922624T 1991-10-21 1992-10-14 Kombinerede cellulære og immunosuppressive terapier DK0610345T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78107591A 1991-10-21 1991-10-21
PCT/US1992/008969 WO1993007887A1 (en) 1991-10-21 1992-10-14 Combined cellular and immunosuppressive therapies

Publications (1)

Publication Number Publication Date
DK0610345T3 true DK0610345T3 (da) 2000-10-23

Family

ID=25121603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92922624T DK0610345T3 (da) 1991-10-21 1992-10-14 Kombinerede cellulære og immunosuppressive terapier

Country Status (11)

Country Link
US (1) US5670148A (da)
EP (1) EP0610345B1 (da)
JP (1) JPH07500343A (da)
AT (1) ATE194494T1 (da)
AU (1) AU2883192A (da)
CA (1) CA2121487A1 (da)
DE (1) DE69231250T2 (da)
DK (1) DK0610345T3 (da)
ES (1) ES2150424T3 (da)
GR (1) GR3034510T3 (da)
WO (1) WO1993007887A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US6063375A (en) * 1996-09-10 2000-05-16 Medical University Of South Carolina Semiallogeneic cell hybrids and related methods for treating cancer
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
ES2218994T3 (es) * 1998-02-02 2004-11-16 The Johns Hopkins University School Of Medicine Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso.
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
AU2003271042C1 (en) * 1999-06-25 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem In Vitro Micro-Organs and Uses Related Thereto
AU2007229367B2 (en) * 1999-06-25 2011-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem In Vitro Micro-Organs and Uses Related Thereto
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
US8088568B2 (en) 2001-11-05 2012-01-03 Medgentics, Inc. Dermal micro-organs, methods and apparatuses for producing and using the same
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
HRP20120673T1 (hr) 2003-05-01 2012-10-31 Medgenics, Inc. Uporaba dermalnih mikroorgana
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN102886052B (zh) 2006-09-14 2014-07-30 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
CA2802726A1 (en) 2010-06-15 2011-12-22 Medgenics Medical Israel Ltd. Long lasting drug formulations
CA2810838C (en) 2010-09-08 2021-07-06 The Board Of Regents Of The University Of Texas System Somatostatin receptor-based cancer therapy
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769317A (en) * 1983-06-14 1988-09-06 Hefton John M Process for growing human epidermis, product thereof
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5175004A (en) * 1988-12-27 1992-12-29 Matsumura Kenneth N Propagatable, new combinant cells for cellular replacement therapy
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
EP1041142A3 (en) * 1991-07-15 2007-10-24 Oklahoma Medical Research Foundation Universal donor cells

Also Published As

Publication number Publication date
EP0610345A1 (en) 1994-08-17
US5670148A (en) 1997-09-23
AU2883192A (en) 1993-05-21
EP0610345B1 (en) 2000-07-12
ATE194494T1 (de) 2000-07-15
DE69231250D1 (de) 2000-08-17
GR3034510T3 (en) 2000-12-29
ES2150424T3 (es) 2000-12-01
WO1993007887A1 (en) 1993-04-29
CA2121487A1 (en) 1993-04-29
EP0610345A4 (en) 1997-01-15
DE69231250T2 (de) 2001-03-15
JPH07500343A (ja) 1995-01-12

Similar Documents

Publication Publication Date Title
DK0610345T3 (da) Kombinerede cellulære og immunosuppressive terapier
AU2953895A (en) Multi-stage cascade boosting vaccine
ES2193143T3 (es) Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
DK66692A (da) En mammal cytokin, il-11
IT8323559A0 (it) Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
ATE198621T1 (de) Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28
NZ506214A (en) Therapy for alpha-galactosidase A deficiency
FR2709309B1 (fr) Compositions cellulaires, préparation et utilisations thérapeutiques.
ES2143539T3 (es) Uso de un agente fotosensibilizador.
DK0668772T3 (da) Specifik immunsystemmodulering
DE69110877D1 (de) Idiotypen-impfung gegen b-zell-lymphoma.
ES2093607T3 (es) Rna bicatenario para la correccion de anomalias en complejos inmunes circulantes y en la funcion de los monocitos.
NO890046D0 (no) Disubstituerte pyridiner.
ATE285247T1 (de) Krebstherapie mit lymphotoxin
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
ES437197A1 (es) Procedimiento para preparar 5-feniltetrazoles sustituidos.
IT8705253A0 (it) Sedia con sedile oscillante indietro e in avanti.
Walsh et al. Further studies on in vitro suppression of rotavirus using a purified fraction of bovine lecithin.
IT1253656B (it) Perfezionata custodia di bilie per giochi di biliardo o simili che puo' chiudersi solo se tutte le bilie vengono rimesse nella medesima
ATE286127T1 (de) Verabreichung der therapeutischen proteine durch implantation der genetischen modifizierten zellen in das omentum
Szuromi Designer dendritic-cell therapy
ES251741U (es) Colchones para camas articuladas.
FUKUSHIMA My Polysaccharide Therapy of Haman Cancer and the Study on Polysaccharide by Hamashima et al
陳五福 Blind children's psychomotility and rehabilitation
KNOLL The effects of storage on irradiated red blood cells: An in vitro an in vivo study(M. S. Thesis)